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Abstract
Background: Dendritic cells (DCs) isolated from tumor bearing animals or from individuals with solid tumors display 
functional abnormalities and the DC impairment has emerged as one mechanism for tumor evasion from the control 
of the immune system. Ductal pancreatic adenocarcinoma (PDAC), the most common pancreatic cancer, is recognized 
as a very aggressive cancer type with a mortality that almost matches the rate of incidence.
Methods: We examined the systemic influence ductal pancreatic adenocarcinoma (PDAC) exerted on levels of 
peripheral blood DCs and inflammatory mediators in comparison to the effects exerted by other pancreatic tumors, 
chronic pancreatitis, and age-matched controls.
Results: All groups examined, including PDAC, had decreased levels of myeloid DCs (MDC) and plasmacytoid DCs 
(PDC) and enhanced apoptosis in these cells as compared to controls. We found elevated levels of PGE2 and CXCL8 in 
subjects with PDAC, and chronic pancreatitis. Levels of these inflammatory factors were in part restored in PDAC after 
tumor resection, whereas the levels of DCs were impaired in the majority of these patients ~12 weeks after tumor 
removal. Our results prove that solid pancreatic tumors, including PDAC, systemically affect blood DCs. The 
impairments do not seem to be tumor-specific, since similar results were obtained in subjects with chronic pancreatitis. 
Furthermore, we found that PDAC patients with a survival over 2 years had significant higher levels of blood DCs 
compared to patients with less than one year survival.
Conclusions: Our findings points to the involvement of inflammation in the destruction of the blood MDCs and PDCs. 
Furthermore, the preservation of the blood DCs compartment in PDAC patients seems to benefit their ability to control 
the disease and survival.
Background
Pancreatic duct adenocarcinoma (PDAC) is a lethal
human cancer, with a five year survival rate of less than
5% [1,2]. PDAC is the tenth most common cancer, repre-
senting about 2% [3] of all cases of cancer, the grim prog-
nosis makes it the number four when it comes to cancer
deaths in the western world [2-4]. Despite all research
efforts during the last 50 years, there are still no effective
therapies for PDAC, except for surgical resection which
has a minor impact on the long term survival rate [5].
Consequently, it is of great importance to acquire a
deeper knowledge about the development and progres-
sion of PDAC in order to develop new treatment strate-
gies for this aggressive cancer.
Increasing evidence points to a systemic impairment of
the immune system in individuals with different types of
cancers [6-8] putatively promoting tumor progression
and development. Dendritic cells (DCs) are professional
antigen presenting cells equipped for activation of naïve
T cells and central memory T cells [9,10]. The DCs are
ubiquitously distributed within the body and constitute
less than 1% of peripheral blood mononuclear cells
(PBMCs) [11,12]. Two distinct subtypes of DCs exist in
the peripheral blood, i.e. the myeloid DCs (MDCs) and
plasmacytoid DCs (PDCs). They share several common
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features, such as the expression of high levels of MHC
class II molecules (HLA-DR) and lack of lineage specific
markers (CD3, CD14, CD16, CD19, CD20, and CD56)
[13]. MDCs express high levels of CD11c, BDCA1, and
BDCA3 and myeloid related surface molecules, whereas
PDCs lack the myeloid markers including CD11c, but
they express the IL-3 receptor (CD123) [13]. These two
DC subtypes also differ in their distribution throughout
the body. MDCs are traveling from the bone marrow into
the peripheral blood and/or out in peripheral tissues. The
encounter of pathogens by tissue MDCs initiate their dif-
ferentiation into mature DCs with the ability to migrate
to lymphatic tissue and activate naïve T cells [11]. PDCs
migrate from the bone marrow to the peripheral blood,
but in contrast to MDCs, they relocate directly from the
blood into secondary lymphoid tissue without encounter-
ing any antigen and PDC is the main producer of IFN-a in
the body upon activation [13,14].
Several types of solid and blood cancers, such as pan-
creatic, breast, prostate, hepatocellular, lung, leukemia
and squamous cell head and neck carcinomas, are accom-
panied by impaired function and reduced numbers of
DCs [15-20]. This imbalance in the circulating DC pool is
not just exclusively a finding in cancer, but is also
observed in patients with chronic infections, such as
HIV-1, hepatitis B, and hepatitis C, atopic dermatitis, and
in autoimmune diseases, such as psoriasis arthritis, and
rheumatoid arthritis [12,21-23].
The connection between these medical conditions is
some degree of chronic inflammation, caused either by
the tumor mass, infectious agents, or by autoreactive
immune cells. The immune system serves to counteract
the attack; which for a short period of time has beneficial
consequences and under normal circumstances promotes
the healing. However, it can be harmful when an inflam-
mation becomes chronic and cause tumor escape from
the immune surveillance [24,25], for instance as a result
of dysfunctional immune cells.
In the present study, we investigated how the PDAC
affect the MDCs and PDCs existing in peripheral blood.
In addition, we wanted to study whether these popula-
tions of DCs return to normal after the tumor resection,
which should be expected if the tumor was the only cause
of the inflammation. We found that the PDAC, and other
cancers located in the pancreas, such as biliary duct ade-
nocarcinoma (BDAC), ampullary carcinoma (AC), and
endocrine carcinoma (EC), all exerted systemic effects on
the MDCs and PDCs, resulting in both reduced numbers
and enhanced apoptosis. Incidentally, chronic inflamma-
tion of the pancreas, i.e. chronic pancreatitis, had the
same effect on the DCs as the different tumors implicat-
ing chronic inflammation as a factor involved in this
impairment. This could indicate that inflammation does
not only directly support the development of the tumor,
for instance by releasing growth stimulatory factors, but
also indirectly by impairing the ability of DCs to activate
immune response directed against the tumor. Of, note a
preservation of the blood DCs compartment in PDAC
patients seems to benefit the patients’ ability to manage
the disease as PDAC patients with a survival over 2 years
had significant higher levels of blood DCs compared to
patients with less than one year survival.
Methods
Patients and controls involved in the study
Twenty ml heparinized peripheral whole blood samples
were obtained from controls, at one occasion, and from
patients at two time points, one week prior surgical
removal of the tumor (Whipple resection) and 8-12
weeks after the surgery. The age matched controls were
recruited randomly from department of Transfusion
Medicine at Linköping University Hospital (Linköping,
Sweden) and from the senior division of Linköping orien-
teering club. Subjects were consecutively recruited from
the list of patients planned for pancreatic resection after
preoperative radiological evaluation at Linköping Univer-
sity Hospital. The final diagnosis was histologically con-
firmed by two pathologists, independently investigating
the samples. The patient group in this study referred to as
billary duct adenocarcinoma (BDAC), are tumors histo-
logically confirmed arising from the distal part of the bil-
lary duct located inside the pancreas. The patients with
pancreatic disease did not receive chemo/radiotherapy
during the time period of the pre or post blood sample
collection and had no long term treatment with cortisone
or NSAID. All samples were coded to protect the identi-
ties of the subjects participating in this study. The study
protocol and patient consent documents were approved
by the Regional Ethics committee in Linköping, Sweden
(Dnr. M38-06). The PDACs were staged according to the
1997 International Union against Cancer classification
(TNM = Tumor, Node, Metastasis).
Separation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from heparin treated whole blood by Ficoll-Paque
PLUS (GE Healthcare, Uppsala, Sweden) density gradient
centrifugation. The plasma layer was collected after the
density centrifugation, aliquoted in cryogenic-tubes and
stored at -70°C until analysis. The cellular interface con-
taining the PBMCs was harvested and washed two times
in Dulbecco's PBS without Ca2+ and Mg2+ (PAA Labora-
tories GmbH, Germany). The PBMCs were resuspended
in PBS supplemented with 0.2% bovine serum albumin
(PAA Laboratories GmbH, Germany) and the cell quan-
tity and viability measured by staining with Trypan blue
(Fisher Scientific, Västra Frölunda, Sweden). The PBMCs
were diluted to 5 × 106 cells/ml and 5 × 105 cells wereTjomsland et al. BMC Cancer 2010, 10:87
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added to the wells of a 96-wells U-bottom plate for exam-
ining the DC frequency and phenotype (see below). The
remaining cells were spun down and re-suspended in
freezing media (fetal bovine serum containing 8% DMSO:
(Sigma-Aldrich, Schnelldorf, Germany) and cryogenic
preserved in a liquid nitrogen freezer.
Flow cytometry monoclonal antibodies
Peripheral blood DC subsets were identified using FITC
conjugated lineage (Lin) cocktail (CD3, CD14, CD16,
CD19, CD20 and CD56), HLA-DR (PerCP), CD11c
(APC), and CD123 (PE) monoclonal antibodies (mab)
(Becton Dickinson, Stockholm, Sweden). Detection of
apoptotic cells in peripheral blood was done by staining
with Annexin V (APC) protein (Becton Dickinson, Stock-
holm, Sweden) in combination with FITC conjugated Lin
cocktail, HLA DR PerCP and PE CD123 for PDCs or PE
CD11c for MDCs.
Flow cytometry acquisition and analysis
PBMCs (5 × 105) were suspended in PBS supplemented
with 0.2% BSA (FACS wash) and labeled with lineage
cocktail, HLA-DR, CD11c, and CD123 mabs to detect
MDCs and PDCs. The antibody straining was carried out
at 4°C for 40 min. After the incubation unbound antibody
was removed by spinning down the samples and replac-
ing the supernatant with new FACS wash. This procedure
was repeated 3 times. Detection of apoptotic DCs in the
PBMCs was done by staining with Lin cocktail, HLA-DR,
CD11c (for MDC) and Lin cocktail, HLA-DR, CD123 (for
PDC) followed by incubation both sets with Annexin V
protein for 15 min at 4°C. Four color flow cytometry was
performed using a FACS Calibur flow cytometer (Becton
Dickinson, San Jose, CA), analyzing 5 × 105 PBMCs for
detection of apoptotic MDCs and PDCs and 2 × 105
PBMCs for determining the quantity of MDCs and PDCs.
The acquired data were analyzed using the FLOW-JO
software, v7.0 (Tree Star Inc, Ashland, OR).
Cytokine array and ELISA
Plasma cytokine profiles were analyzed by Bio-Plex™
Human cytokine 27-plex panel (Biorad, Laboratories,
Inc.). The plasma was thawed, processed, and analyzed as
recommended by the manufacturer. The cytokine panel
was analyzed using Luminex 100™ (Luminex, Inc) plate
reader and data processed using the corresponding pro-
gram. Concentrations of plasma PGE2 metabolites (Cay-
man Chemicals Company, Ann Arbor, USA) and TGF-β
(EBioscience, Inc. San Diego, USA) were measured by
EIA and ELISA, respectively, according to the manufac-
ture protocols.
Statistics
All groups were tested using Kruskal-Wallis one-way
analysis of variance by ranks and when they were found
significant followed by Mann-Whitney U test. P values <
0.05 were considered to be statistically significant. Corre-
lation analysis of the data was performed using the Spear-
man rank correlation of nonparametric data.
Results
Characteristics of patients and controls
52 patients and 20 age matched controls were recruited
to participate in this study. The cancer patients were
divided according to cancer type, such as pancreatic duct
adenocarcinoma (PDAC) (N = 25), ampullary carcinoma
(AC) (N = 6), billary duct adenocarcinoma (BDAC) (N =
4) and endocrine carcinoma (EC) (N = 5). Furthermore,
seven patients that underwent surgery for suspected
tumor in the pancreas and turned out to have chronic
pancreatitis (CP) (N = 7) were also included in this study.
In six individuals the pancreatic tumor was deemed none
resectable at laparotomy however they were included in
the pre surgery group and termed none resectable pan-
creatic tumor (NRPT) (N = 6). Detailed characteristics of
the different patient groups and controls are summarized
in Table 1. The patients that fulfilled the criteria for surgi-
cal resection of the tumor mass donated peripheral blood
around one week before (pre) resection and 8-12 weeks
after (post) resection. The results obtained from individ-
uals with PDAC and other pancreatic cancers and
chronic pancreatitis were compared with twenty ran-
domly selected age matched controls.
Peripheral blood MDCs and PDCs are diminished in 
patients with pancreatic tumors, including PDAC, and 
chronic pancreatitis
Several solid cancers display impaired function and num-
bers of blood DCs [15-20,26,27]. In the case of pancreatic
cancer Yanagimoto et al found that both the circulating
MDC numbers and their function were impaired [15,26].
We examined both MDCs and PDCs in peripheral blood
from patients diagnosed with PDAC and compared this
to levels found in other tumors located in the pancreas
and age matched controls. The frequency of DCs was dis-
tinguished by flow cytometry by gating on HLA DR posi-
tive (gate R2) and lineage negative cells (i.e. to exclude
other cell types). This population contains two DC sub-
types, which can be distinguished from each other by gat-
ing on cells positive for CD11c which correlate to MDCs
(gate R3) or for CD123 which correlate to PDCs (gate R4)
(Figure 1A: representative data from one healthy control
and one individual with PDAC). The frequency of MDCs
and PDCs in blood was measured as the percentage of
total PBMCs. This may not give the exact same levels as if
analyzed as total numbers of PBMCs per ml blood but
gives accurate values of the decrease in DCs occurring in
individuals with pancreatic cancer compared to age
matched healthy controls. Individuals with PDAC, NRPT,Tjomsland et al. BMC Cancer 2010, 10:87
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and CP all had significant decreased levels of MDCs com-
pared to controls (Figure 1B), whereas the levels of PDCs
were significantly reduced in PDAC, and NRPT as com-
pared to controls (Figure 1B). Our age matched controls
had equivalent levels of MDCs and PDCs as documented
previously for this age group [28,29]. The MDCs consti-
tute a larger population than the PDCs in a healthy indi-
vidual. This relationship was altered in PDAC with a
greater loss among MDCs than the PDCs, which brought
about equal frequencies of these cells within the PBMCs
(Figure 1C). In a few patients with PDAC the blood
MDCs and PDCs were almost gone (Figure 1A; lower
panel) indicating that this disease can exert systemic
impairing effects on immune cells important for main-
taining a functional immunity. Of note, we did not see
any correlation between tumor differentiation grade or
stage and the levels of blood DCs (data not shown). Our
findings confirm the decreased frequencies measured in
subjects with pancreatic cancers and other types of can-
cers [16-20]. The reasons why the MDCs and PDCs are
more afflicted in PDAC patients than BDAC, AC, and EC
are unclear, but could be due to the level of inflammation
caused by the different tumors or to behavioral differ-
ences of the tumors.
The blood MDCs and PDCs impairment persist in the 
majority of patients with PDAC and other cancers in the 
pancreas 12 weeks after tumor removal
Surgical removal of primary tumors can reverse tumor
induced immunosuppression [30]. The recovery seems to
take time as normalized levels of MDCs were only found
in PDAC subjects that had been disease free 12 months
after the tumor removal, whereas patients with recurrent
disease or metastasis had no significant increase in these
cells at this time point [26]. Of note, a significant decrease
in blood DCs was seen initially six weeks post the breast
cancer surgery [31]. To evaluate if the resection of the
tumor in patients with PDAC or other cancers in the pan-
creas restored or lowered the blood DC levels, the levels
of MDCs and PDCs were assessed 8 to 12 weeks after
Table 1: Patient characteristics and tumor identification and staging
Control PDAC NRPT BDAC AC EC CP
N Patients 
Pre surg.
2 0 2 5 64657
N Patients 
Post surg.
N / A 1 6 646
M a l e s1 2 1 5 53623
F e m a l e s 8 1 0 11034
Median age 
(range)
66 (49-86) 68 (47-78) 66 (51-74) 75 (65-78) 67 (53-75) 58 (46-67) 67 (59-72)
TNM
1A 13
1 B 4 131
2A 1 1
2B 19 3 1
3 1
41
Differentia
tion
G1 5 2 2
G2 13 1 3
G3 7 3
Not 
evaluated
13
Pancreatic ductal adenocarcinoma (PDAC), None resectable pancreatic tumor (NRPT), billary duct adenocarcinoma (BDCA), ampullary 
carcinoma (AC), endocrine carcinoma (EC), chronic pancreatitis (CP), not applicable (N/A), Tumour, Node, Metastasis (TNM), number (N)Tjomsland et al. BMC Cancer 2010, 10:87
http://www.biomedcentral.com/1471-2407/10/87
Page 5 of 14
Figure 1 Characterization and quantification of MDCs and PDCs. (A) PBMCs isolated from individuals with pancreatic duct adenocarcinoma 
(PDAC) (1 week pre surgery) and healthy age matched volunteers were analyzed for MDCs and PDCs levels by flow cytometry. The PBMCs stained 
with different direct conjugated mabs to distinguish the MDC and PDC from the rest of the cells. The gating was set to exclude debris (R1) and second 
gate (R2) was set on Lineage (FITC) negative and HLA DR (PerCP) positive cells. The MDCs were identified as Lin-HLA DR+ CD11c+ cells (R3) and PDCs 
as Lin-HLA DR+ CD123+ cells (R4). Top panel shows the dot plots from a healthy volunteer and the bottom panel shows the dot plots from an indi-
vidual with PDAC. (B) Percentage of MDCs (top panel) and PDCs (lower panel) prior tumor resection in healthy controls, PDAC, none resectable pan-
creatic tumor (NRPT), billary duct adenocarcinoma (BDAC), ampullary carcinoma (AC), endocrine carcinoma (EC), and chronic pancreatitis (CP). (C) 
Correlation of MDC and PDCs numbers (% out of PBMCs) between controls and PDAC. Control: Solid line and black circles r2 = 0.50. PDAC: striped line 
and white circles r2 = 0.098. Statistically significant differences between individuals with pancreatic disease and healthy controls are indicated as; * = 
p < 0.05, ** = p < 0.005, *** = p < 0.001
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resection. The percentage of MDCs and PDCs were sig-
nificantly increased in some of the subjects after tumor
resection, whereas others surprisingly had even lower
levels than before the tumor resection (Figure 2A, B, C,
D , E ,  and 2 F ).  T he  am ou n ts  of  MDC s  incr eased m or e
than 30% in 8 of the individuals with PDAC (Figure 2B)
whereas only 3 individuals had a more than 30% increase
in PDCs (Figure 2B). Only 3 patients with PDAC, among
all patients and type of cancer examined, had total recov-
ery of MDCs and PDCs post surgery (Figure 2C; example
of patient with full recovery) and this correlated with
decreased levels of inflammatory factors seen post sur-
gery. Surprisingly, the tumor removal even provoked a
further decrease in MDCs (n = 3) and PDCs (n = 5) in
some of the subjects examined in this study. Moreover ,
this decrease post surgery was also seen for patient with
AC, EC, and CP (Figure 2D, E, and 2F). Explanations for
why the DC subsets did not return to normal or even
Figure 2 Resection of pancreatic tumor mass restored the MDCs and PDCs in some subjects. (A) Percentage of MDCs (top) and PDCs (bottom) 
of total PBMCs in healthy age match controls and pre and post tumor resection in individuals with pancreatic duct adenocarcinoma (PDAC) (B) Pre 
and post tumor resection levels of MDCs (top) and PDCs (bottom) in individuals with PDAC. (C) Dot plots showing the percentage of MDCs (CD11c+) 
and PDCs (CD123+) pre and post tumor resection in a subject with PDAC with fully recovered DC populations 12 weeks post surgery. Percent of MDCs 
(top) and PDCs (bottom) of total PBMCs in healthy age match controls and pre and post resection in individuals with (D) ampullary carcinoma (AC), 
(E) endocrine carcinoma (EC) and (F) chronic pancreatitis (CP). Statistically significant differences between individuals with pancreatic disease and 
healthy controls are indicated as; * = p < 0.05, ** = p < 0.005, *** = p < 0.001
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decreased post surgery could be due to, the high recur-
rence rate seen among surgical treated PDAC patients,
that the surgically procedure itself induced a setting with
more inflammation or that the initial inflammation had
not been cleared. The immune system by it self should
not require longer time to recover as the levels and func-
tions of DCs in most of HIV-1 infected individuals starts
to recover soon after the viral load is abolish [21]. In con-
clusion, our results point to an induction of a systemic
impairment of the immune system and its cells, i.e. blood
MDCs and PDCs, by the tumor mass and/or fibrotic
mass. This impairment was reversed in some individuals
when the primary tumor was removed and the inflamma-
tion resolved.
Increased numbers of circulating Lin-HLA DR+ CD123- 
CD11c- cells in peripheral blood from individuals with 
ductal pancreatic adenocarcinoma
Accumulation of lineage- (lin-) HLA DR+CD11c-CD123-
blood cells (non DC) coincides with a reduction in the
CD11c+ DC and/or CD123+ DCs in subjects with breast
cancer, prostate cancer, and malignant glioma [32]. We
noticed that absolute numbers of the non DCs were com-
parable between controls and the different pancreatic
cancer subjects with the exception for BDAC, which had
a decrease in the total numbers of these cells (data not
shown). Of note, even if the absolute numbers of these
cells remained the same did the composition of the lin-
HLA DR+ population change with significantly increased
frequency of non DCs, and decreased PDCs and MDCs
for PDAC, NRPT, AC, EC, and CP (Figure 3A). The
resection of the tumor mass did not diminish the elevated
levels of non DCs in the lin- HLA DR+ cell population
(Figure 3B). The type of cell or cell progenitor that the
non DC population corresponds to needs further evalua-
tion, however we can exclude leukocytes such as normal
monocytes, macrophages, B cells, T cells, NK cells, neu-
trophils, eosinophils, basophils, MDCs, and PDCs. Inter-
estingly, Pinzon-Charry et al showed that this non DC
population increases with metastatic disease compare to
local disease and controls suggesting that there is an asso-
ciation with disease augmentation [32]. The reasons for
why this cell population did not decline to a higher extent
in our cohort could be due to their disease status or too
short time frame from the surgery to have restored the
blood composition.
Elevated levels of apoptotic blood MDCs and PDCs in PDAC 
and chronic pancreatitis
Immune cells circulating in peripheral blood such as
MDCs, PDCs, and T cells in individuals with breast can-
cer, melanoma and head and neck cancer are affected by
the solid tumors as they display an increased spontane-
ous programmed cell death, i.e. apoptosis [33-35]. We
used the Annexin V protein to detect apoptotic cells in
the PBMCs from healthy controls or individuals with
PDAC, other cancers in the pancreas and CP (Figure 4A).
The amounts of apoptotic MDCs and PDCs were signifi-
cantly higher pre surgery in all pancreatic cancers besides
for EC (Figure 4A, B, C, D, and 4E). The levels of apopto-
sis in MDCs and PDCs from PDAC patients post surgery
were similar to the levels seen pre surgery. In contrast,
apoptosis of PDCs and MDCs increased after surgery in
EC (Figure 4D) and AC showed the same tendency (Fig-
ure 4C). Notably, the individuals with CP had the highest
level of MDCs and PDCs apoptosis both pre and post
surgery (Figure 4E). The reasons behind the increase in
apoptotic cells post surgery could be enhanced and/or
changed composition in inflammatory factors during the
Figure 3 The non DC in lin-HLA DR+ cell population is increased 
in individuals with different types of pancreatic cancers and 
chronic pancreatitis. Percentage of non DC (lin-HLA DR+ CD11c-
CD123-) within the lin-HLA DR+ cell population in healthy age match 
controls and pancreatic duct adenocarcinoma (PDAC), none resect-
able pancreatic tumor (NRPT), billary duct adenocarcinoma (BDAC), 
ampullary carcinoma (AC), endocrine carcinoma (EC), and chronic pan-
creatitis (CP) prior surgery (A) and after surgery (B). The proportion of 
non DC was estimated as the mean percentage of the total amount of 
lin-HLA-DR+ cells. Statistically significant differences between individ-
uals with pancreatic disease and healthy controls are indicated as; * = 
p < 0.05, ** = p < 0.005, *** = p < 0.001.
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healing process. We found a significant negative correla-
tion of the levels of PDCs found in peripheral blood prior
and after surgery with the levels of apoptosis among these
cells from individuals with PDAC (Figure 4F, and 4G),
whereas this correlation for MDCs only was significant
for the post surgery samples (Figure 4F, and 4G). This
finding may indicate that the decrease in DC in individu-
als with PDAC and other types of diseases in the pancreas
could be due to increased apoptosis.
Elevated PGE2 and CXCL8 in plasma from individuals with 
PDAC
Results points to that the COX-2 product PGE2 mediated
PDAC cellular invasiveness through an ERK/Ets-1-
dependent induction of MMP-2 expression and activity
[36]. We found here significantly elevated PGE2 levels in
individuals with PDAC both pre- and post surgery even if
the levels decreased after surgery (Figure 5A, B, C, and
5D). The PGE2 levels were not elevated pre or post sur-
gery in the other pancreatic tumors, i.e. BDAC, AC, and
EC (Figure 5A, B, C, and 5D). Incidentally, CP had also
elevated PGE2 levels but was not found statistically signif-
icant (Figure 5A). Other immune regulatory factors have
been found elevated, i.e. IL-10, which have been
described as negative indicator for survival of patients
with different types of cancers. IL-10 in serum from
patients with hepatocellular carcinoma correlates with
Figure 4 Increased spontaneous apoptosis among the MDCs and PDCs in individuals with PDAC and other types pancreatic cancers. (A) 
Percentage apoptotic MDCs (top panel) and PDCs (lower panel) of total MDCs and PDCs prior tumor resection in controls, pancreatic duct adenocar-
cinoma (PDAC), none resectable pancreatic tumor (NRPT), billary duct adenocarcinoma (BDAC), ampullary carcinoma (AC), endocrine carcinoma (EC), 
and chronic pancreatitis (CP). Percent apoptotic MDCs (top) and PDCs (bottom) of total MDCs and PDCs in healthy age match controls and pre and 
post tumor resection in individuals with PDAC (B), AC (C), EC (D) and CP (E). Correlation between percent apoptotic MDCs and level of MDCs (left) 
and correlation between percent apoptotic PDCs and level of PDCs (right) in individuals with PDAC pre tumor resection (F) and post tumor resection 
(G). The numbers of Annexin V positive MDCs and PDCs were measured as the percentage of Annexin V+ cells out of the total amount of MDCs or 
PDCs. Statistically significant differences between individuals with pancreatic disease and healthy controls are indicated as; * = p < 0.05, ** = p < 0.005, 
*** = p < 0.001.
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Figure 5 Elevated levels of inflammatory cytokines in individuals with pancreatic duct adenocarcinoma. PGE2 levels in plasma from pancreatic 
duct adenocarcinoma (PDAC), none resectable pancreatic tumor (NRPT), billary duct adenocarcinoma (BDAC), ampullary carcinoma (AC), endocrine 
carcinoma (EC), and chronic pancreatitis (CP) pre (A) and post (B) tumor resection compared to levels in healthy age matched controls. CXCL8 levels 
in plasma from PDAC, NRPT, BDAC, AC, EC, and CP pre (C) and post (D) tumor resection compared to levels in healthy age matched controls. CXCL8 
levels in plasma from PDAC pre and post (E) tumor resection compared to levels in healthy age matched controls. Statistically significant differences 
between individuals with pancreatic disease and healthy controls are indicated as; * = p < 0.05, ** = p < 0.005, *** = p < 0.001.
Pre Surgery A B
C
C
o
n
t
r
o
l
P
D
A
C
B
D
A
C
A
C
 
E
C
 
C
P
 
**
0
50
100
150
P
G
E
2
i
n
 
p
g
/
m
l
N
R
P
T
Post Surgery
P
D
A
C
A
C
E
C
C
P
*
0
50
100
150
P
G
E
2
i
n
 
p
g
/
m
l
C
o
n
t
r
o
l
P
D
A
C
A
C
E
C
C
P 0
20
40
60
C
X
C
L
8
 
i
n
 
p
g
/
m
l
**
* ***
0
20
40
60
C
X
C
L
8
 
i
n
 
p
g
/
m
l
** * *
C
o
n
t
r
o
l
P
D
A
C
B
D
A
C
A
C
 
E
C
 
C
P
 
N
R
P
T
0
5
10
15
20
25
*** *
**
Control Pre PDAC Post PDAC
C
X
C
L
8
 
i
n
 
p
g
/
m
l
D
ETjomsland et al. BMC Cancer 2010, 10:87
http://www.biomedcentral.com/1471-2407/10/87
Page 10 of 14
decreased number of DCs and immature DCs subsets
[16]. However, we could not observe any significant
increase in IL-10 levels in our samples compared to con-
trols (data not shown). Similar inflammatory components
and downstream effectors have been found to be elevated
in CP and PDAC, such as CXCL8, an activator of inflam-
matory NF-kB cascade and associated with tumorigene-
sis by promoting angiogenesis and metastasis [37]. In
addition, mRNA CXCL8 are over expressed in ~80% of
PDAC tissue samples compared to normal surrounding
tissue [38]. The individuals with PDAC, NRPT, EC, and
CP had significantly elevated levels of serum CXCL8 pre
surgery (Figure 5C). Post surgery, PDAC and AC were the
only diseases that had elevated levels of CXCL8 (Figure
5D). Interestingly, the removal of the tumor mass or sus-
pected to be tumor mass (massive fibrosis) lowered the
CXCL8 levels for PDAC, EC, and CP but only signifi-
cantly for PDAC (P = 0.008) (Figure 5E). We investigated
the levels of TGF-β and several other inflammatory fac-
tors in our samples and could not see any significant
increase or decrease of these factors in any of the individ-
uals with different tumors in the pancreas (data not
shown). In summary, our findings point to systemic
effects exerted by the presence of solid tumor and chronic
inflammation in the pancreas that create elevated levels
of immunoregulatory soluble factors such as CXCL8 in
peripheral blood.
Long time PDAC survivors are presented with more 
circulating DCs than short time survivors
The total amount of blood DCs pre surgery were com-
pared between patients with PDAC surviving less than
one year (n = 7) (short time survivors) and patients sur-
viving more than two years (n = 6) (long time survivors)
after surgery. The rest of our patient cohort had less time
than 2 years since their surgery so they did not fit these
categories for long and short time survivors. Data from
our patient cohort showed a significant difference in the
levels of blood DCs between the group with short (0.38%)
and long time (0.64%) survival (Figure 6A). Of note, both
groups had decreased amount of total blood DCs com-
pared to healthy controls (1.08%) (Figure 6A). To investi-
gate the importance of the amount of circulating MDCs
and PDCs for patient survival, the PDAC patients were
divided into two groups; one group with the 12 lowest
and one group with the 12 highest levels of blood MDC
((≤0.25% and >0.25% MDCs) and PDC (≤0.14% and
>0.14% PDCs)). The low MDC and PDC groups had a
similar one year survival rate of 58%, compared to 83% for
the high MDC and PDC groups (Figure 6B, and 6C).
Some of the other tumors found in pancreas, i.e. amp-
ullary and endocrine carcinoma have higher 5 years sur-
vival rates (60%) [39,40] and both carcinoma groups were
found with similar DC levels pre surgery (0.73% and
0.76%, respectively) as the patients with PDAC with long
time survival (0.64%) (Figure 6D). Hitherto, we have not
found any correlations between the patients' survival
times and the level of inflammatory factors CXCL8 and
PGE2 in their peripheral blood. Our data show the con-
nection of longer survival time and level of DCs in the
blood compartment in patients with PDAC and this need
to be addressed in a bigger cohort of patients and as far as
we know has this not been shown previously and need
further elucidation.
Discussion
DCs have been recognized as the main initiators of the
adaptive immune response and play the pivotal role of
tumor surveillance in healthy individuals. The number of
peripheral blood DCs appears to be decreased in several
types of cancer, including pancreatic cancer [15-
20,31,32]. An opposing finding has been shown for levels
of DC in individuals with melanoma, which had
increased levels of both MDCs and PDCs with the high-
est in stage I disease but even stage IV had elevated levels
[41]. Findings from several types of solid cancers imply
that anti-tumor immunity may be related to the number
and/or functions of DCs [15-17,19,20,26]. Our results
indicate that there is a significant decrease in the amount
of MDCs and PDCs in peripheral blood from patients
with different types of pancreatic cancers, including
PDAC, but also for chronic inflammation in pancreas, i.e.
chronic pancreatitis. A decrease in the MDC and an
increase in the PDC subsets have previously been
described for PDAC [15]. The latter observation are con-
tradicting the results we have obtained in the present
study for PDAC and other pancreatic cancer as well as in
previous findings for different adenocarcinoma
[17,20,31]. These differences are probably due to the defi-
nition of PDCs as CD11c-/lin-/HLA DR+ without using
any specific marker for PDCs, which will include a non
PDC population besides the PDCs [15].
The peripheral Lin- HLA DR+ cell population contains
MDCs, PDCs, and cells that are lin-HLA-DR+CD123-
CD11c-  (non DC). Our findings show a significantly
increased frequency of non DCs among the Lin- HLA
DR+ population in patients with PDAC. This corrobo-
rates a previous study by Pinzon-Charry et al displaying
an increase in this population in breast cancer, prostate
cancer, and malignant glioma [32]. These lin- HLA-
DR+CD11c-CD123- cells might be a specific pre DC
population but they have less efficient antigen presenting
function and generated an inadequate immune response
compared to MDCs and PDCs [32]. Whether these cells
are MDCs and PDCs, that have impaired phenotype and
functions due to the systemic effect by the disease, or if
they comprise a separate cell population of different ori-
gin or a progenitor for one of the blood lymphocyte willTjomsland et al. BMC Cancer 2010, 10:87
http://www.biomedcentral.com/1471-2407/10/87
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need further elucidation. The increased proportion of
this non-DC population among HLA DR+ cells appears
when the MDC and PDC numbers decreases. Conversely,
the diminished levels of DCs could be due to the
enhanced apoptosis seen in both DC subsets in individu-
als with PDAC and other types of cancers in the pancreas.
There was a negative correlation between levels of PDC
and levels of apoptotic cells, which supports the involve-
ment of program cell death as one component in the
decrease. Of note, the frequency of apoptotic DCs
remained the same or increased after the surgical
removal of tumors (PDAC, EC, and AC) or inflamed tis-
sue (CP) and the reason for the increased apoptosis could
be enhanced inflammation secondary to the surgical pro-
cedure or the healing process. Increased apoptosis in the
blood DCs have previously not been described for differ-
ent types of pancreatic cancers or chronic pancreatitis,
whereas MDCs, PDCs, and T cells in individuals with
breast cancer, melanoma, and head and neck cancer have
been shown to have increased levels of apoptosis [33-35].
Taken together, these data prove that the solid tumor
exert systemic modulatory effects on the immune system.
Dysfunctional DCs exist in many cancers including
PDAC, where impairment of T cell stimulatory function
among the MDCs has been detected [15]. Another exam-
ple is breast cancer, which besides decreased T cell stimu-
latory ability, exhibits decreased IL-12 and increased IL-
10 production [17]. It's likely that individuals with PDAC,
Figure 6 Long-time survivors have more DCs compared to short-time survivors. (A) Percent DCs of total PBMCs in healthy age match controls 
and pre tumor resection in PDAC patients surviving less than one year (short-time survivor) and more than two years survival (long-time survivor). (B 
and C) Comparison of the one year survival between the PDAC patient group with the lowest (N = 12) and highest (N = 12) levels of MDCs (≤0.25% 
and >0.25%) and PDCs (≤0.14% and >0.14%), respectively. (D) Percent DCs of total PBMCs in PDAC patients with more than two years survival (long-
time survivor) and in patients with ampullary carcinoma (AC) and endocrine carcinoma (EC) patients. Statistically significant differences between in-
dividuals with pancreatic disease and healthy controls are indicated as; * =p < 0.05, *** = p < 0.001.
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and other pancreatic cancers, with decreased amounts of
MDCs and PDCs and increased level of the non DCs pro-
vide a setting were the DCs in blood and tissue are inade-
quate to initiate a sufficient immune response against the
tumor. Surgical removal of primary tumors can reverse
the tumor induced immunosuppression [30], which
points to the tumor and surrounding stroma cells as gen-
eral sources of inflammation inflicting impairment in the
MDCs and PDCs. So, when resecting this inflammatory
catalyst the immune system should get a second chance
to reorganize and possibly kill remaining tumor cells.
Unfortunately , this seems to have taken place only in a
minority of the PDAC patients in a timely manner but on
the other hand, these patients seem to have a complete
recovery of the circulating DC populations. This failure
to normalize MDC in subjects with PDAC was also seen
in a recent study 2.5 to 13 weeks post surgery [26] and
Pinzon-Charry et al even found a further decrease in
blood DCs six weeks post breast cancer surgery [31].
T u m o r s  h a v e  be e n  r e f e r r ed  t o  as  w o u n d s  t h a t  n ev e r
heal, due to their ability to create an inflammatory
microenvironment [42]. Resection of the tumor should
principally rescue the body from this chronic wound, but
it seems likely that the healing process after surgery by
itself contributes to the impairment of the circulating
DCs as we found increased apoptosis in all pancreatic
cancer groups and CP and even a further decrease in the
frequency of DCs in many of subjects. Patients with early
breast cancer disease showed minimally reduced DC lev-
els at diagnosis but displayed a prolonged period (one
year) of marked DC suppression after tumor resection
[31]. For the majority of PDAC patients this time frame is
too long since the disease gives them a shorter mean sur-
vival span than it takes for the DCs to recover.
Production of residual inflammatory and/or additional
factors induced and produced during the healing process
could be blamed for the sustained negative effect exerted
on the DCs. Cyclin E1, epithelial growth factor (EGF)
[37], IL-6, CXCL8, IL-10, and IL-1RA have all been
shown to be elevated in individuals with pancreatic can-
cer [43,44] and high IL-6 or IL-10 levels correlated to
poor survival [43]. Over expression of CXCL8 mRNA
was found ~80% of PDAC tissues compared to corre-
sponding normal surrounding tissue [38] and CXCL8 was
a l s o  p r e s e n t  i n  C P  [ 3 7 ] .  W e  f o u n d  e l e v a t e d  l e v e l s  o f
plasma CXCL8 in PDAC, EC, and CP pre surgery and
that CXCL8 decreased after tumor resection. Of note, it
has been shown that CXCL8 in PDAC is associated with
tumor genesis by promoting angiogenesis and metastasis
[38] but not with survival [43]. Furthermore, CXCL8 is a
chemoattractant that will attract many different cell types
expressing CXCR1 or CXCR2 including DCs [45] and the
presence of CXCL8 in blood may affect their ability to
exit the blood stream and affect their viability. Our find-
ings do not show correlation between the increased
plasma levels of CXCL8 and the amount of MDCs and
PDCs, neither to the level of apoptosis or patient survival.
The levels of CXCL8 decreased significantly in the blood
from PDAC patients post surgery but this had no direct
effects on the post surgery levels of MDCs or PDCs.
Taken together, our findings indicate that CXCL8 is not
directly involved in the depletion of blood DCs in PDAC
or other pancreatic tumor patients but do not exclude
that the recovery of DCs may take longer time than the
normalization of inflammatory factors, such as CXCL8,
in blood.
COX-2 enzyme expression is found in several cancers
including PDAC and it's involved in cancer differentia-
tion, apoptosis, metastasis, and angiogenesis [46-50]. We
found the COX-2 metabolite PGE2 to be elevated signifi-
cantly only in PDAC patients and tumor resection low-
ered the levels to almost normal. Increased levels of PGE2
in plasma seem to be a specific feature for PDAC and a
possible marker for distinguish PDAC from other tumors
in the pancreas, but further test must be performed. Of
note, PGE2 is known to affect the DC function including,
antigen presentation, maturation, and T cell activation
[51] and this could be true for the MDCs and PDCs in
PDAC. Furthermore, patients with chronic pancreatitis
had also elevated levels but the PGE2 did not normalize
after surgery. The increased plasma levels of PGE2 did not
correlate to the amount of MDCs and PDCs, level of
apoptosis or patient survival. However, the high expres-
sion of PGE2 and CXCL8 in PDAC patients could reflect
the severity of this tumor compared to other pancreatic
tumors [39,40].
Our findings show that patients surviving more than 2
years are represented with more circulating DCs than
short time survivors. Some of the other tumors in the
pancreas, i.e. ampullary and endocrine carcinoma have
high 5 years survival rates (60%) [39,40] and both groups
were found with similar DC levels presurgery (0.73% and
0.76%, respectively) as the patients with PDAC with long
time survival (0.64%). Moreover, the one year survival
was 83% in the group of PDAC patients with the highest
MDC and PDC levels compared to only 58% in the group
of PDAC patients with the lowest MDC and PDC levels.
These findings indicate that the total levels of DCs pre
surgery could predict patient survival. Moreover, our
findings indicate that patients with un-affected blood DC
subsets pre and post, or with normalized DC numbers
post surgery seems to have a survival benefit compared to
individuals with impaired numbers of DCs. The few
patients fitting these characteristics had a survival over
30 months post surgery which is above the mean survival
after pancreaticoduodenectomy for PDAC which isTjomsland et al. BMC Cancer 2010, 10:87
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between 14 to15 months [52-54] indicating the impor-
tance of an intact blood DC compartment.
Conclusions
Individuals with cancer or chronic inflammation in the
pancreas have blood DCs characterized by both reduced
numbers and enhanced apoptosis. The post-surgery fol-
low up revealed a DC compartment still impaired in the
vast majority of individuals examined, but a few individu-
als with cancer had normalized the circulating DC com-
partment. The preservation of the blood DCs
compartment in PDAC patients seems to benefit their
ability to control the disease and survival. If the inability
to restore the DC compartment depends on irreversible
effects exerted by the PDAC or a slow recovery of the
immune system in this type of pancreatic cancer will
need further evaluation seeing that our findings indicate
that the levels of MDCs and PDCs correlate with survival.
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